AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU degradation rate
Number of subjects: 0
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetically guided follow-up of 5-FU
Number of subjects: 0
Study 33020924 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (sex, age, body composition, renal function)
Number of subjects: 0
Study 33021490 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and communication technology-enhanced integration of health and social care (intervention)
Number of subjects: 198
Study 33021490 — intervention group
Group type: COMPARATOR
Intervention: Basic health and social care coordination (comparator)
Number of subjects: 198
Study 33021640 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate (WPI)
Number of subjects: 22
Study 33021640 — intervention group
Group type: EXPERIMENTAL
Intervention: Zein
Number of subjects: 22
Study 33021640 — intervention group
Group type: COMPARATOR
Intervention: Protein-free group
Number of subjects: 22
Study 33021843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 33021843 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33021872 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR T-cell therapy (FMC63-28Z)
Number of subjects: 43
Study 33021869 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19-free surgical pathways
Number of subjects: 9171
Study 33021869 — intervention group
Group type: COMPARATOR
Intervention: No defined pathway
Number of subjects: 9171
Study 33022004 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 2378
Study 33022004 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 2378
Study 33022004 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 2378
Study 33022004 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2378
Study 33022004 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 2378
Study 33022066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (BGB-3111) plus obinutuzumab
Number of subjects: 81
Study 33022101 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic deep brain stimulation (DBS)
Number of subjects: 217
Study 33022101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist dose reduction
Number of subjects: 217
Study 33022101 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative dyskinesias
Number of subjects: 217
Study 33022101 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline apathy
Number of subjects: 217
Study 33022101 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative apathy
Number of subjects: 217
Study 33022101 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation power and position of active contacts
Number of subjects: 217
Study 33022316 — intervention group
Group type: COMPARATOR
Intervention: Physically active men (White NHs)
Number of subjects: 44953
Study 33022316 — intervention group
Group type: COMPARATOR
Intervention: Physically active men (Black NHs)
Number of subjects: 44953
Study 33022316 — intervention group
Group type: COMPARATOR
Intervention: Physically active men (Asian NHs)
Number of subjects: 44953
Study 33022316 — intervention group
Group type: COMPARATOR
Intervention: Physically active women (White NHs)
Number of subjects: 44953
Study 33022316 — intervention group
Group type: COMPARATOR
Intervention: Physically active women (Hispanics)
Number of subjects: 44953
Study 33022376 — intervention group
Group type: EXPERIMENTAL
Intervention: UM171-expanded CB transplant
Number of subjects: 0
Study 33022376 — intervention group
Group type: COMPARATOR
Intervention: Unmanipulated CB transplant
Number of subjects: 0
Study 33022752 — intervention group
Group type: COMPARATOR
Intervention: Educational interventions
Number of subjects: 3282
Study 33022752 — intervention group
Group type: COMPARATOR
Intervention: Environmental interventions (Dust control)
Number of subjects: 3282
Study 33022752 — intervention group
Group type: COMPARATOR
Intervention: Soil abatement
Number of subjects: 3282
Study 33022752 — intervention group
Group type: COMPARATOR
Intervention: Combination of educational and environmental interventions
Number of subjects: 3282
Study 33022852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 252
Study 33023304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Number of subjects: 0
Study 33023304 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33023522 — intervention group
Group type: EXPERIMENTAL
Intervention: Young group (ages 20-39 years)
Number of subjects: 209
Study 33023522 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged group (ages 40-59 years)
Number of subjects: 209
Study 33023522 — intervention group
Group type: EXPERIMENTAL
Intervention: Older group (aged ≥60 years)
Number of subjects: 209
Study 33023522 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 209
Study 33023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline stress, anxiety, and depression
Number of subjects: 356
Study 33023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income <$50,000
Number of subjects: 356
Study 33023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income ≥$100,000
Number of subjects: 356
Study 33023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who lost household income
Number of subjects: 356
Study 33023562 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 356
Study 33023763 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge Eating Disorder (BED) subjects
Number of subjects: 101
Study 33023763 — intervention group
Group type: COMPARATOR
Intervention: Non-BED subjects
Number of subjects: 101
Study 33023948 — intervention group
Group type: EXPERIMENTAL
Intervention: XPO1 inhibitors (selinexor, eltanexor, KOS-2464) combined with melphalan
Number of subjects: 0
Study 33023948 — intervention group
Group type: COMPARATOR
Intervention: Single-agent melphalan
Number of subjects: 0
Study 33023948 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor with melphalan
Number of subjects: 0
Study 33023948 — intervention group
Group type: EXPERIMENTAL
Intervention: XPO1 inhibitors (selinexor, eltanexor) with melphalan
Number of subjects: 0
Study 33023952 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant enzalutamide plus androgen deprivation therapy (ADT)
Number of subjects: 39
Study 33023952 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant enzalutamide plus ADT
Number of subjects: 39
Study 33023999 — intervention group
Group type: EXPERIMENTAL
Intervention: Masimo Radical-7
Number of subjects: 47
Study 33023999 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple iPhone 6S
Number of subjects: 47
Study 33023999 — intervention group
Group type: EXPERIMENTAL
Intervention: Samsung S8
Number of subjects: 47
Study 33024146 — intervention group
Group type: EXPERIMENTAL
Intervention: Callascope (self-imaging)
Number of subjects: 75
Study 33024146 — intervention group
Group type: EXPERIMENTAL
Intervention: Callascope (clinician-based imaging)
Number of subjects: 75
Study 33024146 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exam surveys (Callascope)
Number of subjects: 75
Study 33024146 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care speculum exam
Number of subjects: 75
Study 33024564 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel (FW) squats
Number of subjects: 38
Study 33024564 — intervention group
Group type: COMPARATOR
Intervention: Bodyweight Free (BFW) squats
Number of subjects: 38
Study 33024581 — intervention group
Group type: EXPERIMENTAL
Intervention: NESS-EFTR with sentinel basin dissection
Number of subjects: 20
Study 33024925 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-oil
Number of subjects: 272
Study 33024925 — intervention group
Group type: COMPARATOR
Intervention: placebo control diets
Number of subjects: 272
Study 33024987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 151
Study 33024987 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg once daily
Number of subjects: 151
Study 33025093 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold-based contouring using GTV
Number of subjects: 9
Study 33025213 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day for 3 weeks on, 1 week off)
Number of subjects: 34
Study 33025282 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (GKRS)
Number of subjects: 92
Study 33025378 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 manual push infusion at 0.5 mL/min
Number of subjects: 16
Study 33025378 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 manual push infusion at 1.0 mL/min
Number of subjects: 16
Study 33025378 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 manual push infusion at 2.0 mL/min
Number of subjects: 16
Study 33025378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerability across all flow rates
Number of subjects: 16
Study 33025378 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IgG levels at study start
Number of subjects: 16
Study 33025378 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IgG levels at study end
Number of subjects: 16
Study 33025409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine dressing
Number of subjects: 50
Study 33025481 — intervention group
Group type: EXPERIMENTAL
Intervention: Black carbon dye tattooing of biopsied axillary node (2.0 ml median volume injected, range 0.2-4.2 ml)
Number of subjects: 110
Study 33025481 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary surgery group
Number of subjects: 110
Study 33025481 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) group
Number of subjects: 110
Study 33025481 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT with SNB
Number of subjects: 110
Study 33025481 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT with ALND
Number of subjects: 110
Study 33025481 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT group
Number of subjects: 110
Study 33025481 — intervention group
Group type: COMPARATOR
Intervention: Timing between dye injection and surgery
Number of subjects: 110
Study 33025481 — intervention group
Group type: COMPARATOR
Intervention: Body mass index
Number of subjects: 110
Study 33025481 — intervention group
Group type: COMPARATOR
Intervention: Volume of dye injected
Number of subjects: 110
Study 33025482 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin as first- or second-line therapy
Number of subjects: 83
Study 33025545 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial simplified electrophysiological assessment of the unilateral common peroneal nerve and the sural nerve, performed minimally on alternate days after baseline evaluation.
Number of subjects: 97
Study 33025558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination
Number of subjects: 1345
Study 33025558 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation model
Number of subjects: 1345
Study 33025707 — intervention group
Group type: EXPERIMENTAL
Intervention: L-leucine 700 mg/m
Number of subjects: 55
Study 33025716 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg erythromycin infused intravenously over 20 min
Number of subjects: 6
Study 33026184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk arm protocol therapy
Number of subjects: 123
Study 33026291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 14
Study 33026291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain + Activity
Number of subjects: 14
Study 33026463 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal type 1 diabetes
Number of subjects: 2074
Study 33026463 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal type 1 diabetes
Number of subjects: 2074
Study 33026463 — intervention group
Group type: COMPARATOR
Intervention: Sibling with type 1 diabetes
Number of subjects: 2074
Study 33026463 — intervention group
Group type: EXPERIMENTAL
Intervention: Height velocity (z score/year) in the first 24 months
Number of subjects: 2074
Study 33026463 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 2074
Study 33026630 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 1384
Study 33026630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384
Study 33026630 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA nonresponders
Number of subjects: 1384
Study 33026631 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 1384
Study 33026753 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution, administered once daily for 48 weeks
Number of subjects: 62
Study 33026772 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol propionate 0.01%/Tazarotene 0.045% lotion (HP/TAZ)
Number of subjects: 1
Study 33026892 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric ECG monitoring
Number of subjects: 140
Study 33026892 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group: discharged patients)
Number of subjects: 140
Study 33026965 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0
Study 33026965 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0
Study 33026965 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 0
Study 33027064 — intervention group
Group type: EXPERIMENTAL
Intervention: K-means MTV 2-clusters (MTVhi, MTVlo)
Number of subjects: 25
Study 33027064 — intervention group
Group type: EXPERIMENTAL
Intervention: MTVlo
Number of subjects: 25
Study 33027064 — intervention group
Group type: EXPERIMENTAL
Intervention: MTVhi
Number of subjects: 25
Study 33027064 — intervention group
Group type: EXPERIMENTAL
Intervention: MTV/MTV cluster regions
Number of subjects: 25
Study 33027067 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat (RB150/QGC001)
Number of subjects: 0
Study 33027186 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive group
Number of subjects: 991
Study 33027186 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 negative group
Number of subjects: 991
Study 33027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal sensitization in asthma
Number of subjects: 0
Study 33027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungals and targeted biologic therapy
Number of subjects: 0
Study 33027187 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 33027199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitting to Outcome eXpert (FOX) programming
Number of subjects: 31
Study 33027199 — intervention group
Group type: COMPARATOR
Intervention: Traditional programming methods (Nucleus CI532 trial)
Number of subjects: 31
Study 33027243 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus positive
Number of subjects: 163
Study 33027243 — intervention group
Group type: COMPARATOR
Intervention: Rhinovirus negative
Number of subjects: 163
Study 33027243 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus positive
Number of subjects: 163
Study 33027243 — intervention group
Group type: COMPARATOR
Intervention: Virus negative
Number of subjects: 163
Study 33027243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild upper respiratory complaints reported by parents
Number of subjects: 163
Study 33027260 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified HEART Pathway and point-of-care troponin testing
Number of subjects: 0
Study 33027260 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study 33027294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration perception threshold (VPT) measured using a biothesiometer on big toes, insteps, lateral malleoli, and wrists
Number of subjects: 205
Study 33027294 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression equations for calculating age- and height-specific normal values for VPT
Number of subjects: 205
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL-like regimens followed by allogeneic HSCT
Number of subjects: 398
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 398
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-like regimens without consolidation
Number of subjects: 398
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: NHL-like regimens without consolidation
Number of subjects: 398
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 398
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with lymphoma- or AL-like regimens followed by transplantation
Number of subjects: 398
Study 33027528 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation with allogeneic HSCT
Number of subjects: 398
Study 33027564 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing for detecting genetic variants classified as pathogenic or likely pathogenic
Number of subjects: 127
Study 33027564 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome sequencing
Number of subjects: 127
Study 33027844 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena caval filter plus anticoagulation
Number of subjects: 1388
Study 33027844 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter
Number of subjects: 1388
Study 33027844 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 1388
Study 33028076 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin, bendamustine and rituximab
Number of subjects: 0
Study 33028076 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33028098 — intervention group
Group type: EXPERIMENTAL
Intervention: u-hscTnI (ultra-high-sensitivity cardiac troponin I) measurements
Number of subjects: 263
Study 33028098 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models adjusted for traditional cardiovascular risk factors
Number of subjects: 263
Study 33028169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release budesonide granules (9 mg daily for 8 weeks)
Number of subjects: 61
Study 33028221 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Hypothermia
Number of subjects: 100
Study 33028221 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Normothermia
Number of subjects: 100
Study 33028221 — intervention group
Group type: COMPARATOR
Intervention: Matched control group of acute myocardial infarction (MI) patients
Number of subjects: 100
Study 33028346 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiation followed by 6 cycles of mFOLFOX6 plus avelumab (10 mg/kg) every 2 weeks for 6 cycles.
Number of subjects: 44
Study 33028594 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervascular cellular habitat
Number of subjects: 97
Study 33028667 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-miRNA biomarker panel
Number of subjects: 5248
Study 33028667 — intervention group
Group type: COMPARATOR
Intervention: HP serology
Number of subjects: 5248
Study 33028667 — intervention group
Group type: COMPARATOR
Intervention: PG 1/2 ratio
Number of subjects: 5248
Study 33028667 — intervention group
Group type: COMPARATOR
Intervention: PG index
Number of subjects: 5248
Study 33028667 — intervention group
Group type: COMPARATOR
Intervention: ABC method
Number of subjects: 5248
Study 33028667 — intervention group
Group type: COMPARATOR
Intervention: CEA
Number of subjects: 5248
Study 33028667 — intervention group
Group type: COMPARATOR
Intervention: CA19-9
Number of subjects: 5248
Study 33029116 — intervention group
Group type: EXPERIMENTAL
Intervention: Val group
Number of subjects: 58
Study 33029116 — intervention group
Group type: EXPERIMENTAL
Intervention: Met group
Number of subjects: 58
Study 33029135 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml articaine 2%
Number of subjects: 117
Study 33029135 — intervention group
Group type: COMPARATOR
Intervention: 30 ml bupivacaine 0.5%
Number of subjects: 117
Study 33029262 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed VTE risk stratification protocol with patient education programs (Group A)
Number of subjects: 242
Study 33029262 — intervention group
Group type: COMPARATOR
Intervention: 2005 Caprini risk assessment tool without education programs (Group B)
Number of subjects: 242
Study 33029387 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary PPV with ILM plug
Number of subjects: 0
Study 33029387 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33029427 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pigtail ureteric stent
Number of subjects: 105
Study 33029427 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pigtail ureteric stent with extraction string
Number of subjects: 105
Study 33029427 — intervention group
Group type: COMPARATOR
Intervention: No ureteric stent
Number of subjects: 105
Study 33029552 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed 100% whey protein formula (FA)
Number of subjects: 256
Study 33029552 — intervention group
Group type: COMPARATOR
Intervention: Standard, full-lactose, intact whey/casein infant formulas (FB)
Number of subjects: 256
Study 33029615 — intervention group
Group type: EXPERIMENTAL
Intervention: Major and minor criteria for High Bleeding Risk (HBR) as defined by the Academic Research Consortium (ARC)
Number of subjects: 16580
Study 33029615 — intervention group
Group type: EXPERIMENTAL
Intervention: Major criteria for HBR
Number of subjects: 16580
Study 33029615 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor criteria for HBR
Number of subjects: 16580
Study 33029623 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33029732 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD group
Number of subjects: 636
Study 33029732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 636
Study 33029732 — intervention group
Group type: EXPERIMENTAL
Intervention: PAD type 1
Number of subjects: 636
Study 33029743 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO treatment
Number of subjects: 29